非何杰金氏淋巴瘤市場:KOL的洞察

本報告提供全球非何杰金氏淋巴瘤市場相關調查，提供市場概要，以及已通過核准治療方法，開發平台趨勢，未來預測等資訊。

目錄

摘要整理

現在及未來的治療流程

調查目的

CAR T細胞療法

• 瀰漫性B大細胞淋巴瘤
  • Yescarta(axicabtagene ciloleucel，Gilead)，Kymriah(tisagenlecleucel，Novartis)，及Breyanzi(lisocabtagene maraleucel，BMS)
• 濾泡型淋巴瘤
  • Yescarta(axicabtagene ciloleucel，Gilead)，Kymriah(tisagenlecleucel，Novartis)，Breyanzi(lisocabtagene maraleucel，BMS)
• 被套細胞淋巴瘤
  • Tecartus(brexucabtagene autoleucel，Gilead)，Breyanzi(lisocabtagene maraleucel，BMS)
• 下一代CAR-T細胞療法
  • 重要的洞察概要

T細胞結合雙特異性抗體(BsAbs)

• 認證核可藥/開發平台藥物
  • Lunumio(mosunetsuzumabu，Roche)，Epkinly/Tepkinly(epukoritamabu，Genmab/AbbVie)，Columvi(gurofitamabu，Roche)，odoronekutamabu(Regeneron)

抗體藥物複合體(ADC)

• 已通過核准醫藥品
  • Polivy(poratsuzumabubedochin，Roche)
  • Zynlonta(ronkatsukishimabuteshirin，ADC Therapeutics/Sobi)
• 開發平台醫藥品
  • Adcetris(Brentuximab Vedotin，Seagen/Takeda)

單株抗體(mAb)

• 已通過核准醫藥品
  • Monjuvi/Minjuvi(tafashitamabu，Incyte/MorphoSys)

Bcl-2抑制劑

• 開發平台醫藥品
  • venkurekusuta/venkurisuto(Venetoclax，AbbVie/Roche)

BTK抑制劑

• 已通過核准醫藥品
  • Brukinsa(zanuburuchinibu，BeiGene)，Calquence(akaraburuchinibu，AstraZeneca)，Imbruvica(ibrutinib，Janssen/Pharmacyclics)，Jaypirca(pirutoburuchinibu，Lilly)

今後的治療趨勢

• 重要的洞察摘要

附錄

KOL快報

Bispecific antibodies set to disrupt the non-Hodgkin lymphoma treatment algorithm

In what settings do KOLs expect bispecific antibodies such as Roche's Lunsumio and Columvi, and Genmab/AbbVie's Epkinly, to deliver value? What impact will they have on the current treatment algorithm? What factors lead experts to say Lilly's non-covalent BTK inhibitor Jaypirca is a critical advance for patients with mantle cell lymphoma? KOLs critically assess the prospects of launched and pipeline therapies in the complex NHL sector.

In addition to the full report, licensed users can access the following KOL Bulletins via the Attachments area.

• 18 Sep 2023 KOL Bulletin -- Expert perspective on EC approval of Roche's bispecific Columvi for DLBCL

• 19 Sep 2023 KOL Bulletin -- Views on data from the TRANSCEND FL trial of BMS' CAR-T Breyanzi

Table of Contents

Executive summary (12)

Current and future treatment algorithms

Research objectives (4)

CAR T-cell therapies (31)

• Diffuse large B-cell lymphoma (11)
  • Yescarta (axicabtagene ciloleucel; Gilead), Kymriah (tisagenlecleucel; Novartis) and Breyanzi (lisocabtagene maraleucel; BMS) (11)
• Follicular lymphoma (8)
  • Yescarta (axicabtagene ciloleucel; Gilead), Kymriah (tisagenlecleucel; Novartis) and Breyanzi (lisocabtagene maraleucel; BMS) (8)
• Mantle cell lymphoma (7)
  • Tecartus (brexucabtagene autoleucel; Gilead) and Breyanzi (lisocabtagene maraleucel; BMS) (7)
• Next-generation CAR T-cell therapies (5)
  • Key insights summary (5)

T cell-engaging bispecific antibodies (BsAbs) (21)

• Approved/pipeline drugs (21)
  • Lunsumio (mosunetuzumab; Roche), Epkinly/Tepkinly (epcoritamab; Genmab/AbbVie), Columvi (glofitamab; Roche) and odronextamab (Regeneron) (21)

Antibody-drug conjugates (ADCs) (24)

• Approved drugs (17)
  • Polivy (polatuzumab vedotin; Roche) (9)
  • Zynlonta (loncastuximab tesirine; ADC Therapeutics/Sobi) (8)
• Pipeline drugs (7)
  • Adcetris (brentuximab vedotin; Seagen/Takeda) (7)

Monoclonal antibodies (mAbs) (8)

• Approved drugs (8)
  • Monjuvi/Minjuvi (tafasitamab; Incyte/MorphoSys) (8)

Bcl-2 inhibitors (6)

• Pipeline drugs (6)
  • Venclexta/Venclyxto (venetoclax; AbbVie/Roche) (6)

BTK inhibitors (13)

• Approved drugs (13)
  • Brukinsa (zanubrutinib; BeiGene), Calquence (acalabrutinib; AstraZeneca), Imbruvica (ibrutinib; Janssen/Pharmacyclics) and Jaypirca (pirtobrutinib; Lilly) (13)

Future treatment trends (4)

• Key insights summary (4)

Appendix (4)

• KOL details (4)
  • KOLs from the US (1)
  • KOLs from Europe (2)

KOL Bulletins (3)